

Rec'd PCT/PTC 13 MAY 2005  
PCT/EP 03 / 1 2 6 6 4 #3



Europäisches  
Patentamt

European  
Patent Office

Office européen  
des brevets

REC'D 30 MAR 2004

WIPO

PCT

Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-  
gen stimmen mit der  
ursprünglich eingereichten  
Fassung der auf dem näch-  
sten Blatt bezeichneten  
europäischen Patentanmel-  
dung überein.

The attached documents  
are exact copies of the  
European patent application  
described on the following  
page, as originally filed.

Les documents fixés à  
cette attestation sont  
conformes à la version  
initialement déposée de  
la demande de brevet  
européen spécifiée à la  
page suivante.

BEST AVAILABLE COPY

Patentanmeldung Nr. Patent application No. Demande de brevet n°

02025335.7

**PRIORITY  
DOCUMENT**

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts;  
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets  
p.o.

R C van Dijk



Anmeldung Nr:  
Application no.: 02025335.7  
Demande no:

Anmeldetag:  
Date of filing: 13.11.02  
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Micromet AG  
Staffelseestrasse 2  
81477 München  
ALLEMAGNE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:  
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.  
If no title is shown please refer to the description.  
Si aucun titre n'est indiqué se référer à la description.)

Method for identifying antigen specific B cells

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)  
revendiquée(s)

Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/  
Classification internationale des brevets:

G01N33/48

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of  
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

13. Nov. 2002

New EP Patent Application  
Micromet AG  
Our Ref.: G2536 EP

### **Method for identifying antigen specific B cells**

The present invention relates to a method of identifying a B cell carrying a surface immunoglobulin molecule having a binding site for an antigen of interest comprising contacting a sample putatively containing said B cell with the antigen of interest wherein said antigen is labeled with a first label and with a receptor specifically binding to said surface immunoglobulin molecule wherein said receptor is labeled with a second label and wherein said first label, when being brought into a spatial proximity of between 10 and 100 Angstrom with said second label emits a detectable signal upon activation of said second label by an external source and assessing the presence of said detectable signal, wherein said presence is, in turn, indicative of the B cell carrying a surface molecule having a binding site for the antigen of interest.

In this specification, a number of documents is cited. The disclosure content of these documents including manufacturers' manuals, is herewith incorporated by reference in its entirety.

There is a high medical interest in therapeutic applications of antibodies in human patients. Monoclonal antibodies are routinely produced according to established procedures by hybridomas generated by fusion of mouse lymphoid cells with an appropriate mouse myeloma cell line (first published by Köhler & Milstein, 1975, Nature 256, 495). Therapeutical administration of murine monoclonal antibodies, however, may have severe side effects. For example, in patients with minimal residual colorectal cancer, a murine monoclonal antibody specific for the human 17-1A-antigen decreased the 5-year mortality rate by 30% compared to untreated patients; in total each patient was treated with 900 mg of murine antibody (Riethmüller, Lancet 343(1994), 1177-1183). However, during the course of

antibody treatment patients developed a strong antibody response against murine immunoglobulin.

Mouse antibodies are per definition 100% mouse-derived and are recognized as foreign bodies by the human immune system, resulting in an immune response against the drug, specifically a human anti mouse antibody (HAMA) response. As a result, the antibody drug is neutralised on repeated dosing. This results in rapid clearance of the drug from the body and possible allergic responses. Moreover, preformed HAMAs induced by former antibody treatment or another contact with murine immunoglobulin can severely interfere with later antibody therapies. Therefore, drugs based on murine antibodies can only be used in acute indications, where the patient is treated once or at most twice.

Due to those problems associated to murine antibodies, it has been a challenge to develop methods for the production of antibodies useful for antibody therapy which do not have the disadvantage of producing HAMA.

In one approach, chimaeric antibodies were developed (Boss, 1989, US 4,816,397; Cabilly, 1989, US4,816,567). Chimaeric antibodies are composed of human and non-human amino acid sequences. Such chimaeric antibodies are genetically engineered. They contain approximately 66% human and 33% non-human protein. Accordingly, hybrid antibody molecules have been proposed which consist of amino acid sequences from different mammalian sources. The chimaeric antibodies designed thus far comprise variable regions from one mammalian source, and constant regions from human or another mammalian source (Morrison et al. (1984) Proc. Natl. Acad. Sci. USA., 81:5851-6855; Neuberger et al. (1984) Nature 312: 604-608; Sahagan et al. (1986) J. Immunol. 137:1066-1074; European patent applications EP 04302368.0 (Genentech); EP 85102665.3 (Research Development Corporation of Japan); EP 85305604.2 (Standord); PCT application PCT/GB85/00392 (Celltech Limited). Chimaeric antibodies potentially have improved therapeutic value as they presumably elicit less circulating human antibody against the non-human immunoglobulin sequences. However, an immune response, the so-called human anti-chimaera antibody (HACA) response, is often generated against such drugs.

Therefore, humanised monoclonal antibodies have been designed (Adair, 1999, US-A 5,859,205; Queen, 1996, US-A 5,530,101). Humanised antibodies differ from chimaeric antibodies in that they contain close to 90% human-derived protein sequence, including a largely human-derived variable domain sequence. This is made possible by retaining the minimum non-human sequence required to retain the original monoclonal antibody's binding properties. The variable domain of humanised antibodies usually consists of a human antibody framework (FR) and the complementary determining regions (CDRs) of the parental (murine) antibody, which provides the binding specificity. Humanised antibodies, however, tend to have reduced substrate-binding activity and may still provoke an immune response. (Dr. Sydney Welt, May 1998, Cancer Research Institute (CRI) Symposium, New York, "The use of humanized antibodies to treat cancer"). Generally, to prevent the problems of HAMA and HACA, therapeutic antibodies with minimal immunogenicity but which still possess high substrate binding activity, would be preferable.

To achieve this goal, it has, of course, been envisaged to use therapeutic antibodies or antibody derivatives that are completely human by their amino acid sequence and wherein the immunogenic profile of the human antibody idotype is minimized by using human Ig-variable regions likely to be tolerated by the human immune system.

Several techniques have been developed to generate human antibodies.

1.) Human hybridoma or other human cell immortalisation methods have been developed but proved to be quite inefficient in generating human antibody producing cell lines compared to the murine hybridoma technology. Human monoclonal antibodies are difficult to produce by cell fusion techniques since, among other problems, human hybridomas are notably unstable, and removal of immunized spleen cells from humans is not feasible. It has proven difficult to find suitable human myeloma-fusion partners. Human-human hybrids are not as stable and do not produce as great a quantity of antibody as can be attained in mouse-mouse fusion systems. With the application of in vitro immunisation using human cells, another difficulty is that human cells contain various repressed lethal viruses which may be activated and expressed upon hybridisation and subsequent recombination. These viruses can be infectious, and pose issues of health and safety for lab

workers. Furthermore, it is difficult to totally remove all lethal viruses from the monoclonal antibodies, and thus such antibodies cannot readily be used therapeutically for humans. Another difficulty of the hybridoma technology lies in the fact that naturally rarely occurring antibodies and corresponding B lymphocytes are rarely immortalized. Namely, the size of the original pool of hybridomas is limited by the number of stable antibody clones that can be generated and screened in a reasonable time and by the intrinsic inefficiency of the process. Thus, of the antibody cells present in the population of immunized cells that are subjected to the fusion process, only a small fraction form stable antibody-producing hybrids and are available to a screen for the desired antibody. Furthermore, antibodies must be subcloned in a tedious growth and subcloning process during which the desired antibody-forming cell may be lost. If the desired antibody is formed by only a small fraction of antibody-forming cells involved in an immune response and is, for example, an antibody which mimics an enzyme or an auto-reactive antibody, the likelihood that this antibody will be produced by any of the stable hybrids available for screening is correspondingly small.

2.) Human antibodies have become much more readily accessible since the availability of transgenic mice expressing human antibodies (Brüggemann, *Immunol. Today* 17 (1996), 391-397). The transgenic technology involves the introduction of human antibody genes into the mouse genome. Advantages of transgenic technologies include fully human protein sequences, high affinity, and fast and efficient production processes. However, a potential drawback of the technique is that it is difficult to introduce enough of the human antibody genes to ensure that the mice are capable of recognising the broad diversity of antigens relevant for human therapies. In addition, transgenic animals are very difficult to generate and antibodies with certain specificities even more laborious to find.

3.) Another way for human antibody production is the combinatorial antibody library and phage display technology allowing the in vitro combination of variable regions of Ig-heavy and light chains (VH and VL) and the in vitro selection of their antigen binding specificity (Winter, *Annu. Rev. Immunol.* 12 (1994), 433-455). By using the phage display method, rare events like one specific binding entity out of  $10^7$  to  $10^9$  different VL/ VH- or VH/ VL-pairs may be isolated; this is especially true when the

repertoire of variable regions has been enriched for specific binding entities by using B-lymphocytes from immunized hosts as a source for repertoire cloning. With combinatorial phage libraries, the problem occurs that often the frequency of specific binding entities is substantially lowered in naturally occurring antibody repertoires. This is particularly true for cases of antibodies binding to self-antigens. Random combinations of VL- and VH- regions from a self-tolerant host resulting in combinatorial antibody library of a conventional size ( $10^7$  to  $10^9$  independent clones) most often are not sufficient for the successful in vitro selection of rare antibody-specificities by the phage display method. To isolate low frequency antigen-specificities it is possible to use very large combinatorial antibody libraries that compensate by the library size for the low frequency of auto-reactive antibodies in naturally occurring repertoires. Combinatorial antibody libraries exceeding a size of  $10^9$  independent clones, however, are difficult to obtain because of the current technical limit of the transformation efficiency for plasmid-DNA into E. coli-cells.

To avoid the self-tolerance mediated bias in naturally occurring antibody repertoires, that underrepresents auto-reactive antibodies and markedly decreases the chances of isolating antibodies specifically recognizing self-antigens, approaches using semisynthetic or fully synthetic VH-and/ or VL-chain repertoires have been developed. For example, almost the complete repertoire of unrearranged human V-segments has been cloned from genomic DNA and used for in vitro recombination for functional variable region genes, resembling V-J or V-D-J-recombination in vivo (Hoogenboom, J. Mol. Biol. 227 (1992), 381-388; Nissim, EMBO J. 13 (1994) 692-698; Griffiths, EMBO J. 13 (1994), 3245-3260). Usually, the V-D-/D-J-junctional and the D-segment diversity mainly responsible for the extraordinary length and sequence variability of heavy chain CDR3 as well as the V-J-junctional diversity contributing to the sequence variability of light chain CDR3 is imitated by random sequences using degenerated oligonucleotides in fully synthetic and semisynthetic approaches (Hoogenboom (1994), supra; Nissim, supra; Griffiths, supra; Barbas, Proc. Natl. Acad. Sci. U.S.A 89 (1992), 4457-4461).

Synthetic human libraries often have the disadvantage that they are difficult and laborious to create and screening for a certain specificity needs high throughput.

tools. Further, VL/VH- or VH/VL-pairs selected for binding to a human antigen from such systematic repertoires based on human V-gene sequences are at risk of forming immunogenic epitopes that may induce an undesired immune response in humans (Hoogenboom, TIBTECH 15 (1997), 62-70). Especially the CDR3-regions derived from completely randomised sequence repertoires are predestined to form potentially immunogenic epitopes as they have never had to stand the human immune surveillance without being recognized as a foreign antigen resulting in subsequent elimination. This is equally true for human antibodies from transgenic mice expressing human antibodies as these immunoglobulin molecules have been selected for being tolerated by the murine but not the human immune system.

Quite often the success of any one of these methods largely depends on the frequency with which the desired antigen specificity is represented in the source material. Antibodies with an antigen specificity directed against an antigen that the individual was previously immunized with, will constitute a high percentage of the total reservoir of antigen-specificities present in the pool. Antibodies of naïve, unprimed B cells, where no previous immunization has taken place, will be represented to a much lower percentage in the total reservoir of antigen-specificities present in the pool. The most rarely occurring antibodies are those that have undergone a previous counter-selection like the antigen-specificities of auto-reactive antibodies. Furthermore, antibodies directed against self red blood cells are also part of antibodies occurring with very low frequency. The chances of isolating an antibody with antigen-specificity against an auto-antigen or against a self red blood cell by the methods described above are extremely low.

Prior art approaches to solve isolate low-frequency antibody-specificities include those described in US-A 5,326,696 and in US-A 5,627,052. US-A5,326,696 assigned to Tanox Biosystems, Inc., describes a method for identifying and isolating low-frequency B-cells that relies on the use of two antigen populations wherein the antigen populations differ by their fluorescent labels. B-cells carrying Ig molecules with the desired specificity for the antigen on their surface will bind to the labeled antigens. Using a multi-channel FACS machine, those B-cells are isolated that have picked up both type of antigens, i.e. antigens labeled with the first and with the second fluorescent label. The fidelity of the method may be enhanced by counter



selecting against autofluorescent cells and sticky cells of various leukocyte subpopulations as well as by additionally marking B-cells with a labeled receptor for B-cell specific surface antigens such as CD19,  $\gamma$ -chain,  $\kappa$  or  $\lambda$ -chain, or Fc-receptors. In the case that the additional selection means are employed, fluorescent labels different from the labels attached to the desired antigens are necessary. Thus, the claimed invention envisages four different labels for an optimal selection and a correspondingly equipped FACS machine. It is of note that the optional additional labelling of surface components of B-cells cannot enhance to any large extent the frequency of B-cells expressing antibody to the desired antigen but is useful for clearing the non-specific contamination of T-cells, macrophages, monocytes, B-cells expressing IgM and other cells.

US-A 5,627,052 assigned to B. R. Centre, Ltd., describes a process for the identification of a protein of choice, preferably of an antibody with a desired specificity from which the variable regions may be cloned and subsequently employed to generate a novel protein of interest. The claimed invention makes use of a functional assay for identifying the antibody of interest. The functional assay relies on the suspension of antibody-forming cells in a medium wherein the medium comprises an indicator system which indicates the presence and location of the antibody forming cells. The indicator medium may contain, for example pathogenic microorganisms and cells susceptible in viability to said pathogenic microorganisms. If the sample to be accessed comprises an antibody with specificity to the pathogenic microorganism, it will inhibit infection of the susceptible cells by the pathogenic microorganism. As a consequence and surrounding the cell capable of producing the desired antibody, a layer of cells susceptible to the pathogenic microorganism will grow due to the inhibition of the pathogenic effects normally exerted by the microorganism due to the presence of the antibody. Cells producing the desired antibody may then be subjected to conventional recombinant DNA technologies and  $V_H$  and  $V_L$  region genes involved in the antibody production may be cloned. Alternatively, the selection system makes use of, for example, haemolytic plaques assays involving coupling the antigen to the erythrocyte surface, rosetting techniques or techniques relying on the enhanced growth or morphological change of cells due to the presence of antibodies having an effect analogous to a protein

selected from a group of differentiation and growth factors. The claimed method is allegedly suitable to detect antibody forming cells even if present in a very low frequency in a sample only. However, the selection step is time consuming and only useful for the analysis of a confined number of antibody-producing cells.

As discussed, the methods described above for the generation of human or humanized antibodies are not suitable for the convenient and reliable isolation of very rare antibodies, in particular non-immunogenic auto-reactive antibody-specificities. On top of this, the prior art did not even disclose methods to reliably identify and isolate corresponding rare B cells. The technical problem underlying the present invention therefore was to provide such methods. Starting from rarely naturally occurring B cells, antibody genes giving rise to the desired antibody specificities might then be cloned and used for the desired downstream developments.

The solution to said technical problem is achieved by providing the embodiments characterized in the claims.

Accordingly, the present invention relates to a method of identifying a B cell carrying a surface immunoglobulin molecule having a binding site for an antigen of interest comprising (a) contacting a sample putatively containing said B cell (aa) with the antigen of interest wherein said antigen is labeled with a first label and (ab) with a receptor specifically binding to said surface immunoglobulin molecule wherein said receptor is labeled with a second label and wherein said first label, when being brought into a spatial proximity of between 10 and 100 Angstrom with said second label emits a detectable signal upon activation of said second label by an external source and (b) assessing the presence of said detectable signal, wherein said presence is, in turn, indicative of the B cell carrying a surface molecule having a binding site for the antigen of interest.

The term "surface immunoglobulin molecule" refers to immunoglobulin molecules inserted by way of their C-terminus into the surface of B cells. In principle, this term is well established in the art; see, for example, W.E. Paul (ed.) "Fundamental Immunology", second edition 1989, Raven Press, New York, Roitt et al, "Immunology", 1985, The C. V. Mosby Company, St. Louis, MO. It includes sIgM,

sIgD, sIgA, sIgG and sIgE and all subclasses thereof. In the following, these surface immunoglobulins are also referred to as IgM, IgD, IgA, IgG and IgE.

The term "receptor" refers to a molecule that is capable of specifically recognizing and binding to an epitope of the surface immunoglobulin molecule. Potential receptors include aptamers and antibodies.

The term "activation" according to the present invention describes a transient or perpetual change in the energy level of the respective molecules. Advantageously, "activation" means an excitation generated e.g. by a laser source. In another preferred interpretation, "activation" relates to a substrate turnover, such as coelenterazine, which is a substrate for the enzyme luciferase (Wang, 2002, Mol. Genet. Genomics 268 (2), 160-168).

A "detectable signal" means, in accordance with the present invention, any signal that can be qualitatively or quantitatively assessed by means of a suitable signal detector. Such signals include phosphorescent, bioluminescent and fluorescent signals.

The term "B-cell" in the present invention comprises all lymphocytes that develop in the adult bone marrow or in the fetal liver and are destined to produce antibodies. All different stages in the development of a B cell are included, such as pre B cells, naïve, unprimed B-cells, which have not come into contact with an antigen yet or mature B cells, as well as plasma cells, which have been activated to proliferate and mature through antigen contact.

As has been outlined above and in other terms, the invention solves the recited technical problem by a highly sensitive positive selection approach. B cells are isolated from a sample e.g. peripheral blood mononuclear cells (PBMCs) from the blood stream and labelled using two different detectable labels such as fluorescent dyes. One label is coupled to the antigen of choice for which a corresponding antigen-specificity shall be found. The second label is coupled to a receptor such as

a monoclonal or polyclonal (serum-derived) antibody specific for the surface immunoglobulin molecule. The surface immunoglobulin may be an IgD surface marker on naïve unprimed B cells (Fig. 1 schematic). Most cells from the cellular sample will not bind the antigen. Only very few antigen-specific B cells will recognize the antigen. In those cases, in our example the IgD-coupled label (such as a fluorochrome) and the antigen coupled label (such as second fluorochrome) come into close spatial proximity. In case of antibody coupled labels, such antibodies may be monoclonal or polyclonal antibodies, which may be directed against any epitope on the surface receptor which is not the antigen binding epitope or an epitope too distant from the antigen binding epitope in order to allow fluorescence resonance energy transfer between the two labels to occur. If the fluorochromes chosen constitute a donor-acceptor pair, then there exists a FRET system. The selection of antigen-specificities is highly sensitive and specific due to the discriminative power of the Förster distance. Therefore, even the isolation of extremely rare antigen-specificities like auto-reactive antigen-specificities is possible. This is preferably accomplished by the use of a fluorescence activated cell sorter (FACS) in combination with fluorescence resonance energy transfer (FRET) as a selection principle. The principles of FACS-based analysis as well as of the FRET principle are well established in the art and briefly outlined herein below.

FACS (fluorescence activated cell sorter) denominates a cytofluorimetric device that allows the analysis and isolation of cell populations according to the scattering and the fluorescent signals of those cells. Therefore, the cells get labelled with fluorescent dyes which are usually coupled to antibodies that recognize a certain cell type (Römpf Lexikon, 1999, Biotechnologie und Gentechnik, Georg Thieme Verlag, 2<sup>nd</sup> edition). The resulting signals are detected using e.g. a photo multiplier, CCD- and CMOS-detectors, and photon counting assemblies.

Fluorescence energy transfer (FRET) is a process by which a fluorophore donor in an excited state may transfer its excitation energy to a neighbouring chromophore acceptor non-radioactively through dipole-dipole interactions. In principle, if one has a donor molecule whose fluorescence emission spectrum overlaps the absorbance spectrum of a fluorescent acceptor molecule, they can exchange energy between

one another through a non-radioactive dipole-dipole interaction. This energy transfer manifests itself by both quenching of donor fluorescence in the presence of acceptor and increased emission of acceptor fluorescence. Energy transfer efficiency varies most importantly as the inverse of the sixth power of the distance separating the donor and acceptor chromophores. The critical distance is the so-called Förster distance (usually between 10-100 Angstrom). The phenomenon can be detected by exciting the labelled specimen with light of a wavelength corresponding to the maximal absorption (excitation) of the donor and detecting light emitted at the wavelengths corresponding to the maximal emission of the acceptor, or by measuring the fluorescent lifetime of the donor in the presence and absence of the acceptor. The dependence of the energy transfer efficiency on the donor-acceptor separation provides the basis for the utility of this phenomenon in the study of cell component interactions. The conditions that need to exist for FRET to occur are: (1) the donor must be fluorescent and of sufficiently long lifetime; (2) the transfer does not involve the actual reabsorption of light by the acceptor; and (3) the distance between the donor and acceptor chromophores needs to be relatively close (usually within 10-50 Angstrom) (Herman, 1998, Fluorescence Microscopy, Bios scientific publishers, Springer, 2<sup>nd</sup> edition, page 12)

A further possibility to generate a signal is given with the so called „bioluminescence energy transfer“ (BRET) system. This system is described in Arai et al., 2001, Anal. Biochem. 289 (1), 77-81. Said BRET system can also be used for the present invention and its sensitivity can be even higher than that of FRET. The example given in Arai et al. comprises Renilla luciferase, (Rluc) and enhanced yellow fluorescent protein (EYFP).

Further, intramolecular energy transfer has been shown between Renilla luciferase (Rluc) and Aequorea “green fluorescent protein” (GFP) (Wang et al. 2002, Mol. Genet. Genomics 268(2), 160-8). In the presence of the luciferase substrate coelenterazine a GFP emission could be measured at the wave length of 508 nm, without UV excitation. Thus a “double emission” at 475 nm (luciferase) and 508 nm (GFP) could be measured.

Furthermore, donor acceptor interactions in the systematically modified lanthanides such as Ru(II)-Os(II) have been described (Hurley & Tor, 2002, J. Am. Chem. Soc. 124(44), 1323-13241). Analyzes showed a Förster dipole-dipole energy transfer mechanism.

The present invention, in contrast to US-A 5,326,696, relies on only one detectable signal and thus significantly simplifies the handling of the experiments as well as the necessary technical equipment of the FACS machine employed. In addition, the method of the present invention bears advantages over the prior art multi-color approach because multi-color staining can easily cause false positive results due to unspecific staining. For example, if phycoerythrin (PE) is used as fluorochrome it can, due to its size, cause quenching of the fluorescein signal. As a consequence, the multi color staining signal can be lost. This is also shown in Reference example 1, where a multi color sort system was used in order to isolate B cells specific for a defined antigen. With this multi color system it was however not possible to reliably sort the B cells specific for said antigen. The FRET signal generated by the method of the present invention, however, only occurs if both probes (antigen and anti-surface immunoglobulin) have bound very closely together (Förster distance). Additionally, the fluorochromes used in multi-color FACS selection partially overlap, especially Texas red and allophycocyanin (APC). Therefore, it is problematic to apply this assay as a selection principle to very rare cells. The extreme gating, which is necessary in this case, results in quenching of signals. Accordingly, cells which actually fulfil the selection criteria, are expected to be lost. Further, without the use of a propidiumiodide counter staining to eliminate dead cells the multi-color FACS assay becomes even more difficult to handle and the recovery of living antigen-specific auto reactive B cells is expected to be extremely poor. Recovery of living cells is important, however, if subsequent efficient RNA recovery and V region cloning are envisaged.

Another principal problem with the multi-color FACS selection method is unspecific binding. Antigenic peptides are prone to stick unspecifically to cell surfaces or bind unspecifically to other surface proteins like CD45. Even with the additional signal

from anti IgG antibody conjugate or anti CD19 antibody conjugate as suggested in US-A 5,326,696 the false positive signal remains. In the method of the invention, in contrast, unspecific signals are eliminated. The signal only occurs when antigen and anti-surface immunoglobulin have bound very close together (Förster distance). This results in a significantly increased specificity.

In accordance with the present invention and according to the example fluorochromes Fluorescein and Alexa Fluor 546, it is preferred that the spatial proximity amounts to at least 50 Angstrom.

The mammalian immune systems such as the human immune system selects against immune competent cells and molecules that are specific for self-antigens. Dysregulation of the immune system in this regard may result in auto-immune diseases such as rheumatoid arthritis or allergy. However, therapeutically it would be advantageous to have auto-reactive antibodies that are directed to antigens expressed in the mammalian, and in particular, the human body. Such antigens are, for example, tumor associated antigens. B cells producing such auto-reactive antibodies are relatively efficiently depleted from naturally occurring antibody repertoires due to the mechanisms mediating self-tolerance. 90% of the B cells produced every day die without ever leaving the bone marrow (Kuby, 2000, Immunology, 4<sup>th</sup> edition, W.H. Freeman and company, page 273). Some of this loss is attributed to negative selection and clonal deletion. However, some of those auto-reactive B cells escape the clonal deletion process and enter the peripheral human blood stream. This reservoir of natural fully human antibodies potentially represents a broad diversity of antigen specificities and can serve as a valuable source for the isolation of fully human antibody sequences useful in therapeutic applications. Due to the negative selection process in the bone marrow, however, such fully human auto-reactive antibody-specificities are extremely rare in the total reservoir of antibody-specificities. Clonal deletion operates early in life (Burnet, 1959, The clonal selection theory of acquired immunity, Cambridge University Press, London). Later in life all auto-reactive B cells not eliminated during ontogeny are prevented from expanding and secreting anti-self antibodies by a compensatory suppressor mechanism (Cunningham A.J., 1976, Transplant. Rev. 31, 23). Therefore, auto-reactive antibodies are produced only in minute quantities allowed

by the suppressor mechanism (Tomer & Schoenfeld, 1988, Immunological Investigations 17(5), 389-424). It is thus extremely rare to find a certain antigen-specificity against auto-antigens within the population of mature naïve unprimed B cells. Further, primed B cells, which are also present in peripheral blood, are over represented in their antigen-specificity due to clonal proliferation. Accordingly, the probability of finding such antibody-specificities in the peripheral blood stream is very low.

Consequently, in a preferred embodiment of the method of the present invention said B cell is an auto-reactive B cell.

In another preferred embodiment of the method of the present invention said surface immunoglobulin molecule is an IgD, an IgE, an IgM or an IgG. During the antigen-independent phase of B cell development the B cells mature in the bone marrow. Once the B cells express membrane-bound IgM and IgD immunoglobulins they are mature and leave the bone marrow. Subsequently, when those naïve B cells encounter an antigen the cells are activated and switch their immunoglobulin production to other classes like IgG (Kuby, 2000, Immunology, 4<sup>th</sup> edition, W.H. Freeman and company, page 269). Therefore, membrane-bound IgD is a marker molecule for the naïve unprimed B cell population. This is the population which comprises rare auto-reactive antibody producing B cells.

Consequently, in a particularly preferred embodiment said B-cell is a naïve, IgD-positive B-cell.

The method of the invention is suitable, in principle, to identify B cells carrying surface receptors against abundantly occurring or rarely occurring antigens. The specific advantages of the method of the invention in particular take effect when it comes to the isolation of rarely occurring antigens as has been outlined above. Such rarely occurring antigens may belong to the group of receptors and cellular proteins or fragments thereof. In a preferred embodiment of the method of the present invention said antigen of interest is selected from the group consisting of auto-antigens, allergens and immunoglobulins.

The term "auto-antigen" means, in accordance with the present invention, any self antigen which is mistakenly recognized by the immune system as being foreign.



Auto-antigens comprise, but are not limited to, cellular proteins, phosphoproteins, cellular surface proteins, cellular lipids, nucleic acids, glycoproteins, including cell surface receptors .

The problems with the isolation of antibodies against auto-antigens have been detailed herein above. Similarly, antibodies to allergens, in particular belonging to the IgE class, have rarely been identified by conventional technologies. Inter alia, this is due to the low frequency of 0.3 $\mu$ g/ml IgE antibodies in the serum (Kuby, 2000, Immunology, 4<sup>th</sup> edition, W.H. Freeman and company, page 101).

Rheumatoid factors rarely have been isolated as well. Rheumatoid factors are a dominant class of autoantibodies in rheumatoid arthritis and certain other autoimmune syndromes. They are IgM or IgG antibodies formed against IgG immunoglobulins, which is usually triggered by slight alterations of such IgGs. High affinity rheumatoid factor B cells are essentially lacking in high affinity rheumatoid factor transgenic mice. Analysis of bone marrow suggests that central tolerance prevents high affinity rheumatoid factor B cell development, receptor editing, or both (Wang & Shlomchik, 1997, J. Immunol. 159, 1125-1134).

The formation of rare auto-reactive antibodies may also be triggered by environmental factors such as the sun, drugs or infections (Abu-Shakra & Schoenfeld, 1991, Immunol. Ser. 55, 285-313). Such autoantibodies may belong to different immunoglobulin classes and include rheumatoid factor, anti-DNA, anticardiolipin, and anti-red blood cell antibodies. The association between infectious agents and autoimmune disorders was reported with acute infections as well as with infections with a chronic course. The appearance of rheumatic fever was observed following streptococcal infection (Zabriskie, 1982, Pediatr. Ann. 11, 383-396) and the onset of diabetes mellitus type I following mumps or coxsackievirus infection (King et al., 1983, Lancet 1, 1397-1399; Christiansen et al., 1983, Sem. Arthritis Rheum. 17, 1-23). Also, an association between autoimmunity and tuberculosis, syphilis, AIDS, malaria, Leishmania, schistosomias, and mycobacterial infection was reported. Mycobacterial infections for example induce autoimmunity via antigenic similarity between host antigens and mycobacteria. The

antibodies formed against the mycobacteria subsequently cross react with host antigen depending on the patient's genetic background. An example for the frequency of anti-self red blood cell antibodies showed that only 1/104 000 B cells produced anti-self A/B IgM and 1/350 000 B cells made anti-self A/B IgG (Rieben et al., 1992, Eur. J. Immunol. 22, 2713-2717).

Generally, the sample may be any sample putatively containing B cells. For example, the sample may be serum or lymph. In this case, the source of the sample may be any animal, preferably any mammal and most preferably a human. Alternatively, the source may be a spleen, lymph node, bone marrow or other organ that contains B cells or parts thereof. In these cases, it is preferred that the source is a non-human animal. In a further preferred embodiment of the method of the present invention said sample is a sample of essentially purified B cells. This embodiment is particularly useful for lowering the background in the readout system due to the absence of other cells containing surface molecules potentially being a source of cross-reactivities to the antigen or the receptor such as T cells. Essentially purified B cells may be employed according to techniques well established in the art including Ficoll density gradient centrifugation (Ficoll-Paque from Amersham, density 1.077 g/ml, Amersham Biosciences, Buckinghamshire, UK) or use of Miltenyi Columns (i.e. magnetic depletion of T cells, Miltenyi B cell isolation kit, Auburn, CA, USA) and methods described in the appended examples.

In an additional preferred embodiment of the method of the present invention said first label is a fluorophore or fluorochrome. Fluorophores and fluorochromes are fluorescent agents which, as has been detailed above, can efficiently be employed in FACS analyses, advantageously in combination with FRET analyses. In a particularly preferred embodiment of the method of the present invention said fluorophore is Alexa 546. This particularly advantageous fluorophore is employed, in accordance with the present invention, as a FRET acceptor.

In a further preferred embodiment of the method of the present invention said second label is a fluorophore or fluorochrome.

In a particularly preferred embodiment of the method of the present invention said fluorophore is fluorescein, Cy2, or BODIPY\_FL<sup>TM</sup>. These most preferred agents serve in accordance with the invention as a FRET donor.

In another preferred embodiment, said second label is fluorescein and said first label is Alexa 546.

In another preferred embodiment of the method of the present invention said spatial proximity is such that fluorescence resonance energy is transferred from the second to the first label. This technology is also referred to FRET as has been explained above.

Furthermore, advantages of FRET comprise that only the second label, the donor, is excited by a specific wavelength, whereas the signal that is assessed derives from the first label, the acceptor. Thus, a signal only occurs when resonance energy transfer takes places. Consequently, only low background noise occurs and high sensitivity and selectivity of the assay can be achieved.

In a more preferred embodiment of the method of the present invention said receptor is an antibody or a fragment or derivative thereof. Fragments of antibodies include F(ab')<sub>2</sub> and Fv fragments. Derivatives of antibodies are, for example, single-chain Fv constructs, chimeric as well as humanized antibodies; see also, for example, Harlow and Lane, "Antibodies, A Laboratory Manual", CSH Press 1989, Cold Spring Harbor. Antibodies include monoclonal and polyclonal antibodies, i.e. serum antibodies.

In a most preferred embodiment of the method of the present invention said antibody is directed against the Fc-part of the surface immunoglobulin molecule. Antibodies against the Fc part of surface immunoglobulins can be easily prepared according to standard procedures. Cross reactivity with different Ig classes is tested for, e.g., by assessing the replacement rate of binding to the surface Ig constant region of choice vs. the unwanted constant regions in a turbidimetric assay.

Replacement rate of binding to the surface Ig constant region of choice may also be determined by a competitive assay such as an ELISA where the Ig constant region is coated to the wells and competition between differently labelled antibodies or other substances like peptides is measured. The choice of the Fc portion as the receptor target has the advantage that it minimizes the risk of interference of binding of the surface receptor with the desired antigen. The antigen binding epitope of the receptor has to be located at the Fc portion in such a way that the maximal allowable Förster distance of 100 Angstrom can be achieved between the two labels.

In an additional preferred embodiment of the method of the present invention said antibody is an anti-idiotypic antibody, wherein said anti-idiotypic antibody does not interfere with the binding site to the antigen. If this preferred embodiment is selected in the method of the invention, care needs to be taken that the anti-idiotypic antibody, i.e. the antibody directed to the variable region of the surface immunoglobulin, does not interfere with the binding of the surface immunoglobulin with the antigen of choice. Accordingly, an appropriate test must be performed by the practitioner prior to implementing the method of the invention. Such appropriate tests are available in the art; see, for example, tests described in Harlow and Lane, loc. Cit. which may be slightly modified by the person skilled in the art, if desired. Appropriate tests are for example epitope-mapping which uses overlapping peptides and ELISA, dot blots, or PepScan<sup>TM</sup> membranes for detection. Radioactively labelled or fluorescently or bioluminescently labelled peptides may be used for competitive studies in solution.

In a further preferred embodiment of the method of the present invention said external source is a laser source. Again, the laser source is particularly appropriate for performing the FRET assay. In a further embodiment of the method of the present invention said laser source is an Argon laser 488.

In another preferred embodiment of the method of the present invention said detectable signal is a light emission detected by a photomultiplier.

In order to clone antibody variable regions, it is important beforehand to isolate the B cells which have been identified with the method of the present invention. Hence,

in a particularly preferred embodiment of the present invention the method further comprises the step of isolating identified B cells.

The B cells can, for example, be isolated from samples of peripheral blood gained from humans and as described in Example 4 of the present invention.

In a further particularly preferred embodiment, said B cells are "low frequency" B cells. The term "low frequency" as employed in the present invention describes B cells occurring only rarely in the entire pool of B cells of a sample and mammal, respectively. Consequently, in one embodiment, said low frequency B cells occur at a frequency of about 1 low frequency B cell in  $10^5$  of all the B cells in the pool, in another more preferred embodiment they occur at a frequency of about 1 in  $10^6$ , in a more preferred embodiment in a frequency of about 1 in  $10^7$ , in an even more preferred embodiment in a frequency of about 1 in  $10^8$  and in a most preferred embodiment in a frequency of about 1 in  $10^9$  B cells.

An example for low frequency B cells has been mentioned above. This type of rarely occurring B cells produces anti-self red blood cell antibodies in humans (Rieben et al., 1992, Eur. J. Immunol. 22, 2713-2717).

As has been stated above, one of the most important goals of the method of the invention is the cloning of antibody variable regions from the identified B cells. These variable regions may subsequently be employed in the construction of proteins such as antibodies or fragments or derivatives thereof and these agents may be used in therapeutic approaches. Accordingly, in a different preferred embodiment, the method of the present invention further comprises the step of cloning VH- and VL-domains from the selected B cells. Preferably, these V-domains (also referred to as V-regions) comprise the complete functionally rearranged VDJ regions. Alternatively parts thereof such as at least one of the complementarity determining regions may be cloned. For example, RNA or DNA can be isolated from selected single B cells and the VH and VL regions can be cloned via RT-PCR or PCR using specific primers. These V regions then, can be further subcloned. In one of different alternatives, variable regions may also be cloned by generating

cDNA libraries of preferably expanded selected B cells and functionally rearranged variable region genes isolated using appropriate probes. Further suitable approaches have been summarized in US-A 5,326,696. VH and VL regions may be combined according to their natural sequence or in arbitrary combination. The VH/ VL regions may be combined by the means of fusion PCR introducing a linker sequence in between. These VH/ VL fusions may further be subcloned into various antibody formats and constructs like complete antibodies, antibody fragments, single-chain antibodies or bispecific constructs i.e. constructs with two different binding specificities (Sambrook & Russel: Molecular Cloning: A Laboratory Manual, third edition 2001, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York).

In a particularly preferred embodiment of the method of the present invention said cloning comprises isolating RNA from the selected B cell, followed by an RT-PCR and followed by fusing the DNA or fragments thereof into an expression vector.

The vector employed may be a plasmid, cosmid, virus, bacteriophage or another vector used e.g. conventionally in genetic engineering, and may comprise further genes such as marker genes which allow for the selection of said vector in a suitable host cell and under suitable conditions.

Furthermore, the vector used may comprise expression control elements, allowing proper expression of the coding regions in suitable hosts. Such control elements are known to the artisan and may include a promoter, a splice cassette, translation initiation codon, translation and insertion site for introducing an insert into the vector. Preferably, the DNA is operatively linked to said expression control sequences allowing expression in eukaryotic or prokaryotic cells.

Many suitable vectors are known to those skilled in molecular biology, the choice of which would depend on the function desired and include plasmids, cosmids, viruses, bacteriophages and other vectors used conventionally in genetic engineering. Methods which are well known to those skilled in the art can be used to construct various plasmids and vectors; see, for example, the techniques described in Sambrook (1989), loc. cit., and Ausubel, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y. (1989), (1994). Relevant sequences can be transferred into expression vectors where expression of a

particular (poly)peptide/protein is required. Typical expression vectors include pTRE, pCAL-n-EK, pESP-1, pOP13CAT.

The term "control sequence" refers to regulatory DNA sequences which are necessary to effect the expression of coding sequences to which they are ligated. The nature of such control sequences differs depending upon the host organism. In prokaryotes, control sequences generally include promoter, ribosomal binding site, and terminators. In eukaryotes generally control sequences include promoters, terminators and, in some instances, enhancers, transactivators or transcription factors. The term "control sequence" is intended to include, at a minimum, all components the presence of which are necessary for expression, and may also include additional advantageous components.

The term "operably linked" refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. A control sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences. In case the control sequence is a promoter, it is obvious for a skilled person that double-stranded nucleic acid is preferably used.

An "expression vector" is a construct that can be used to transform a selected host cell and provides for expression of a coding sequence in the selected host. Expression vectors can for instance be cloning vectors, binary vectors or integrating vectors. Expression comprises transcription of the nucleic acid molecule preferably into a translatable mRNA. Regulatory elements ensuring expression in prokaryotic and/or eukaryotic cells are well known to those skilled in the art. In the case of eukaryotic cells they comprise normally promoters ensuring initiation of transcription and optionally poly-A signals ensuring termination of transcription and stabilization of the transcript. Possible regulatory elements permitting expression in prokaryotic host cells comprise, e.g., the *P<sub>L</sub>*, *lac*, *trp* or *tac* promoter in *E. coli*, and examples of regulatory elements permitting expression in eukaryotic host cells are the *AOX1* or *GAL1* promoter in yeast or the CMV-, SV40-, RSV-promoter (Rous sarcoma virus), CMV-enhancer, SV40-enhancer or a globin intron in mammalian and other animal cells. In this context, suitable expression vectors are known in the art such as Okayama-Berg cDNA expression vector pcDV1 (Pharmacia), pCDM8, pRc/CMV,

pcDNA1, pcDNA3 (In-vitrogene), pSPORT1 (GIBCO BRL). An alternative expression system which could be used to express a cell cycle interacting protein is an insect system. In one such system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in *Spodoptera frugiperda* cells or in *Trichoplusia* larvae. The coding sequence may be cloned into a nonessential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of said coding sequence will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein coat. The recombinant viruses are then used to infect *S. frugiperda* cells or *Trichoplusia* larvae in which the protein is expressed (Smith, J. Virol. 46 (1983), 584; Engelhard, Proc. Nat. Acad. Sci. USA 91 (1994), 3224-3227).

In a further preferred embodiment, the method of the present invention further comprises the step of expressing said V-domains in an expression system. In a particularly preferred embodiment of the method of the present invention said expression system is of eukaryotic origin. Advantageously, eukaryotic expression systems from yeasts, insects or bacteria, and more preferred from mammals are employed. Such expression systems are commercially available, e.g., from Stratagene or Promega.

In a most preferred embodiment the method of the present invention further comprises the step of generating antibodies or fragments or derivatives from said V-domains. Such derivatives may also comprise a construct comprising a single chain antibody and an effector molecule such as a chemokine, or cytokine, or structural protein and a linker amino acid sequence

These antibodies, fragments or derivatives may, possibly after further manipulations, in particular by recombinant DNA technologies to improve their binding specificity, avidity, half life etc. or to reduce their potential residual antigenicity then be formulated into pharmaceutical compositions or kits.



The pharmaceutical composition produced in accordance with the above may further comprise a pharmaceutically acceptable carrier and/or diluent. Examples of suitable pharmaceutical carriers are well known in the art and include phosphate buffered saline solutions, water, emulsions, such as oil/water emulsions, various types of wetting agents, sterile solutions etc. Compositions comprising such carriers can be formulated by well known conventional methods. These pharmaceutical compositions can be administered to the subject at a suitable dose. Administration of the suitable compositions may be effected by different ways, e.g., by intravenous, intraperitoneal, subcutaneous, intramuscular, topical, intradermal, intranasal or intrabronchial administration. The dosage regimen will be determined by the attending physician and clinical factors. As is well known in the medical arts, dosages for any one patient depends upon many factors, including the patient's size, body surface area, age, the particular compound to be administered, sex, time and route of administration, general health, and other drugs being administered concurrently. A typical dose can be, for example, in the range of 0.001 to 1000  $\mu\text{g}$  (or of nucleic acid for expression or for inhibition of expression in this range); however, doses below or above this exemplary range are envisioned, especially considering the aforementioned factors. Generally, the regimen as a regular administration of the pharmaceutical composition should be in the range of 1  $\mu\text{g}$  to 10 mg units per day. If the regimen is a continuous infusion, it should also be in the range of 1  $\mu\text{g}$  to 10 mg units per kilogram of body weight per minute; respectively. Progress can be monitored by periodic assessment. Dosages will vary but a preferred dosage for intravenous administration of DNA is from approximately  $10^6$  to  $10^{12}$  copies of the DNA molecule. The compositions may be administered locally or systemically. Administration will generally be parenterally, e.g., intravenously; DNA may also be administered directly to the target site, e.g., by biolistic delivery to an internal or external target site or by catheter to a site in an artery. Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose

and sodium chloride, lactated Ringer's, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert gases and the like. Furthermore, the pharmaceutical composition may comprise further agents such as interleukins or interferons depending on the intended use of the pharmaceutical composition.

In a particularly preferred embodiment the method of the present invention further comprises the steps of rearranging all possible combinations of different VH and VL domains.

Thus, VH and VL domains deriving from different B cells can be combined in order to achieve a higher antibody diversity. In addition, the binding affinity and/or avidity of the antibody can possibly be improved.

In a further preferred embodiment, the method of the present invention further comprises the step of generating, bispecific antibody constructs or single chain antibodies.

The term "single chain antibody" refers to an antibody containing one binding specificity for a (preferably predefined) epitope. Single chain antibodies comprise one VL and one VH region and a linker amino acid sequence. Single chain antibodies have been described, for example, in Bejcek, 1995, Cancer Research 55, 2346-2351.

The term "bispecific antibody construct" refers to a construct that comprises two different binding specificities for (preferably predefined) different epitopes and optionally different antigens. Bispecific antibody constructs have been described, for example, in Mack, 1995, PNAS 92, 7021-7025.

In an additional preferred embodiment the method of the present invention further comprises an assay for antibody evaluation. To verify the binding specificity of the antibodies evaluation assays and preferably binding assays may be performed. These binding assays advantageously use the initial fishing antigen or an equivalent thereof. Assays such as ELISA, FACS-based assays, BIAcore<sup>TM</sup>, or dot blot may then be performed.




Additionally, the present invention relates to a device for assessing the presence of a detectable signal as defined in the method as described above, wherein said device comprises a closed system for the detection laser-beam and a catcher tube, and wherein the B cell of interest can be collected as a single cell by means of an electrochemical device which is triggered by an electric signal generated by the FAX device, wherein the electrochemical device moves the nozzle of the steady catcher tube liquid stream for a programmed time over a collecting tube, microtiter plate or other container after a B cell is sorted.

In the device described in US-A 5,326,696 the cells of interest are singled out in drops. Subsequently, the emission is measured and the drops containing the cells of interest are deflected by means of an electrochemical device. However, the method of the invention does not properly function using this device since the signal obtained by measuring single drops is qualitatively not sufficient for use in the method of the invention due to manifold scattering and light loss. Thus, the present invention, including the signal generation and detection, is advantageously carried out in a solid fluid stream, wherein the cells are collected directly from said liquid stream without being singled out beforehand.

Preferred embodiments of this method of the invention include those that have been detailed in accordance with the method of the invention that has been characterized herein above. These preferred embodiments apply mutatis mutandis to this embodiment of the invention.

The figures show:

**Figure 1:**

Schematic drawing representing the detection principle of auto-reactive B cells by FACS sort using FRET as selection principle.  Spotted stars represent a second label like fluorescein coupled to a receptor like anti-IgD antibody, which specifically binds to a surface immunoglobulin molecule on B cells.  White stars represent a first label like Alexa Fluor 546 coupled to an antigen of interest, which is not activated due to lack of spatial proximity to the second donor label.  Black stars represent a first label like Alexa Fluor 546 coupled to an antigen of interest, which is activated by the second donor label, since antigen and receptor have bound closely together on the same surface immunoglobulin molecule.

**Figure 2 :**

FACS images showing the selection of single B cells from a mouse B cell line mixture using FRET. A) 8.18C5 mouse cells stained with donor-fluorochrome fluorescein anti IgG FITC and propidiumiodide (PI), amplification FL2: 490. B) 8.18C5 mouse cells stained with anti IgG FITC and MOG Fc Alexa Fluor 546 and PI showed real FRET signal, amplification FL2: 490. C) 8.18C5 mouse cells stained with MOG Fc Alexa Fluor 546 and PI as FL2 control, amplification FL2: 490. D) 8.18C5 mouse cells stained with anti IgG FITC and MOG Fc Alexa Fluor 546 and PI with increased FL2 amplification of 500. E) 8.18C5 (160  $\mu$ l) and A20 mouse cells mixed and both double stained with anti IgG FITC and MOG Fc Alexa Fluor 546 and PI, amplification FL2: 500. F) as E, but with lowered mixing ratio 8.18C5 (40  $\mu$ l) to A20. G) A20 double stained mouse cells anti IgG FITC and MOG Fc Alexa Fluor 546 and PI, amplification FL2: 500.

**Figure 3:**

A) Analytical agarose gel electrophoresis to test A20- and MOG-primers specificity. GR) Size standard marker (GeneRuler™ DNA ladder Mix, MBI Fermentas, St. Leon-Rot, Germany). 1) cDNA A20 cells preparation 1 plus 5' muB-actin primer and 3' muB-actin primer. 2) cDNA A20 cells preparation 2 plus 5' muB-actin primer and 3' muB-actin primer. 3) cDNA MOG cells preparation 1 plus 5' muB-actin primer and 3' muB-actin primer. 4) cDNA MOG cells preparation 2 plus 5' muB-actin primer and 3' muB-actin primer. 5) cDNA A20 cells preparation 1 plus 5' VH-A20-outside primer and 3' VH-A20-outside primer. 6) cDNA A20 cells preparation 1 plus 5' VH-A20-inside primer and 3' VH-A20-inside primer. 7) cDNA A20 cells preparation 1 plus 5' VH-MOG-outside primer and 3' VH-MOG-outside primer. 8) cDNA A20 cells preparation 1 plus 5' VH-MOG-inside primer and 3' VH-MOG-inside primer. 9) cDNA MOG cells preparation 1 plus 5' VH-MOG-outside primer and 3' VH-MOG-outside primer. 10) cDNA MOG cells preparation 1 plus 5' VH-MOG-inside primer and 3' VH-MOG-inside primer. 11) cDNA MOG cells preparation 1 plus 5' VH-A20-outside primer and 3' VH-A20-outside primer. 12) cDNA MOG cells preparation 1 plus 5' VH-A20-inside primer and 3' VH-A20-inside primer. B) Analytical agarose gel electrophoresis of nested PCR products for selected mouse B cell clones using the A20-primer pairs. GR) (GeneRuler™ DNA ladder Mix, MBI Fermentas, St. Leon-Rot, Germany), lanes 1-8) were nested PCR products from 8 different single selected cells, 9) was a pool of 200 MOG cells used as negative control, 10) was a pool of 200 A20 cells used as positive control, 11) was used as reagent control. C) Analytical agarose gel electrophoresis of nested PCR products for selected mouse B cell clones using the MOG-primer pairs. GR) (GeneRuler™ DNA ladder Mix, MBI Fermentas, St. Leon-Rot, Germany), lanes 1-8) were nested PCR products from 8 different single selected cells, 9) was a pool of 200 MOG cells used as positive control, 10) was a pool of 200 A20 cells used as negative control, 11) was used as reagent control.

**Figure 4:**

FACS images of dilution series experiments. A) 8.18C5 mouse B cells stained with MOG-Fc Alexa Fluor 546 as control reaction (labelling reaction 5). B) 8.18C5 mouse B cells stained with IgG-fluorescein as control reaction (labelling reaction 6). C) 8.18C5 mouse B cells double stained with MOG-Fc Alexa Fluor 546 and IgG-fluorescein as FRET positive control reaction (labelling reaction 7). D) Mixture of A20 mouse B cells and 8.18C5 mouse B cells double stained with MOG-Fc Alexa Fluor 546 and IgG-fluorescein 50% / 50% dilution (labelling reaction 8). E) see D plus gating gate 1=R1 contains cells without FRET signal and gate 2=R2 contains cells with FRET signal.

**Figure 5:**

Excel graph of dilution series experiment (labelling reactions 8-18) showing the specificity of FRET selection.

**Figure 6:**

FACS images of single B cell selection from human blood using FRET. A) Unstained cells, B) cells stained with anti human IgD fluorescein, C) cells stained with anti human IgD Alexa Fluor 546, D) cells double stained with anti human IgD fluorescein and anti human IgD Alexa Fluor 546 as positive gate setting control, E) cells double stained with anti human IgD fluorescein and rCD28 Alexa Fluor 546 for real sorting.

**Figure 7:**

FACS images of multi color sort of human B cells. A) Cells labelled with Cy2-EpCAM antigen 5.00  $\mu\text{g/ml}$ , B) cells labelled with Cy2-EpCAM antigen 2.50  $\mu\text{g/ml}$ ,

C) cells labelled with Cy2-EpCAM antigen 1.25  $\mu\text{g/ml}$ , D) cells labelled with Cy2-EpCAM antigen 0.63  $\mu\text{g/ml}$ , E) cells labelled with Cy2-EpCAM antigen 0.31  $\mu\text{g/ml}$ , F) double stained cells with anti CD45-FITC and anti IgD-PE.

### **Figure 8:**

FACS-based binding assay using A) KATOIII cells as EpCAM positive cells and B) CHO 17-1A transfected cells as EpCAM positive cells. Black line: anti His tag antibody binding as negative control, green line: bispecific scFv anti EpCAM x anti CD3 binding as positive control (Mack, 1995, PNAS 92, 7021-7025), pink line: anti EGFR antibody binding, blue, yellow and dark blue line: three different supernatants of scFv clones selected using multi color FACS sorting (as described in example 6).

### **Figure 9:**

Spectrum overlay of phycoerythrin (PE) and FITC (modified from Molecular Probes online catalogue, Eugene, OR, USA).

The examples illustrate the invention.

### **Example 1**

#### **Selection of single B cells from a mouse B cell line mixture using FRET**

##### ***A) Description of mouse B cell lines used***

Two mouse B cell lines were used to establish and determine the feasibility of FACS based B cell selection using fluorescence resonance energy transfer (FRET) as selection principle. Two mouse B cell lines with different antigen-specificity were chosen:

- A20 cells: undetermined antigen-specificity: The A20 cell line is a BALB/c B cell lymphoma line derived from a spontaneous reticulum cell neoplasm.

found in an old BALB/cAnN mouse (Kim KJ et al., 1979, J. Immunol. 122, 549-554).

The cells express little surface immunoglobulin when grown in Click's medium; however, they express large amounts when grown in RPMI 1640 medium.

The cells can present both alloantigens and protein antigens (Glimcher LH et al., 1982, J. Exp. Med. 155, 445-459).

8.18C5 cells with MOG-Fc antigen-specificity: Litzenburger et al., 1998, J. Exp. Med. 188(1), 169-180 generated a transgenic mouse strain with an anti-MOG heavy chain variable region, derived from the anti-MOG mAb 8.18-C5 "knocked in" for the germline J<sub>H</sub> locus. Such mice exclusively express the 8.18-C5 anti-MOG heavy chain, resulting in generation of approximately 30% MOG-reactivity in the B-cell pool, as assessed by binding to recombinant MOG. Whole lymphocytes from transgenic knock-in mice were prepared from spleen.

Both B cell lines have surface IgG. Therefore, an anti mouse IgG-fluorescein conjugate is supposed to bind to both cell types. The fluorescein dye is the donor dye in the FRET assay. It appears in the FL1 channel of the FACS device. The MOG-Fc-Alexa Fluor 546 conjugate is supposed to accept the fluorescent energy transmitted by fluorescein. This red fluorescence appears in the FL2 channel of the FACS device. However, this energy transfer event only occurs when both dyes are in close proximity towards each other (within the "Foerster distance"). In case the MOG-Fc-Alexa Fluor 546 conjugate binds unspecifically to the surface of the B cell, there can be no signal due to the distance of donor and acceptor dye.

#### *B) Mouse B cell staining*

An amount of 200 000 cells from each B cell line was placed into the wells of a 96 well V-shape microtiter plate and centrifuged at 600g at 20°C for 3min. The supernatant was discarded and antibody solution added consisting of 50µl FACS buffer plus 5µl antibody (either anti mouse IgG-fluorescein or MOG-Fc-Alexa Fluor 546).



Labelling reaction	Cell line	Anti Maus IgG Fluor.	MOG-Fc Alexa 564
1	A20	-	-
2	A20	+	-
3	A20	-	+
4	A20	+	+
5	8.18C5	-	-
6	8.18C5	+	-
7	8.18C5	-	+
8	8.18C5	+	+

The labelling reactions were incubated for 30 min at 4°C. Subsequently, the wells were filled up to 200  $\mu$ l using FACS buffer. Cells were centrifuged as above, the supernatant was discarded. The washing procedure was repeated and cells resuspended in 200  $\mu$ l FACS buffer containing 0.5  $\mu$ g/ml Propidiumiodide as a death marker. Propidiumiodide enters cells with membrane damage (dead cells) and marks them by binding to their DNA. The Propidiumiodide appears in the FL3 channel of the FACS device.

### C) FACS settings and measurements

A FACS sorter (Becton Dickinson, US) was used with the following settings for 8.18C5 cells: FCS E00 1.0, SSC 396, FL1 468 log, FL2 489 log, FL3 495 log.

Labelling reaction 6 (see example 1B) containing only the donor-fluorochrome fluorescein displayed a fluorescent signal between  $10^2$  and  $10^3$  in channel FL1. The compensation used for reaction 6 was FL2 – FL1 24,6%, amplification was FL2: 490 (Fig. 2A). To see true FRET signal reaction 8 was measured. A strong shift in FL2 could be seen (Fig. 2B). Another labelling reaction was measured, reaction 7, to control for unspecific signal in FL2 (MOG-FC-Alexa Fluor 546 conjugate only), amplification FL2 490. With reaction 7 no FL2 shift could be observed (Fig. 2C). When the amplification of FL2 was increased to 500, the FRET signal was detected more clearly (Fig. 2D). As most crucial experiment reactions 4 and 8 were mixed to determine, if the two mouse B cell populations really could be separated by the FRET measurements (Fig. 2E). Both populations are detectable in FL1/FL2 as well

as in FSC/SSC. According to the amount of 8.18C5 added the FRET gate appears fuller and fuller (compare Fig. 2F and 2E). As a direct negative control for the specificity of FRET selection in this mixing experiment reaction 4 was measured (only A20 cells stained). Thereby, no cells could be detected in the FRET gate (Fig. 2G).

As a result of these FACS staining experiments it could be shown that two mouse B cell lines could clearly be separated from each other depending on their antigen-specificity using FRET as the selection method. No FRET signal was generated in non antigen-specific, FRET-negative B cells (Fig. 2G). This is possible due to the specific characteristics of the fluorochromes chosen. Alexa Fluor 546 is not excitable at 488nm. It needs the fluorescence resonance energy transfer from fluorescein.

## Example 2

### Verification of single B cell identity by nested PCR

#### *A) A20- and MOG-primers were tested for their specificity.*

RNA was isolated from  $1.0 \times 10^7$  cells each (Rneasy Mini Kit, Qiagen, Hilden, Germany). Complementary DNA was synthesized (Omniscript RT Kit, Qiagen, Hilden, Germany) using poly (dT)<sub>15</sub> primers (Roche, Penzberg, Germany). Subsequently to the reverse transcription reaction a nested PCR was performed using the following primer pairs:

5'  $\beta$ - actin mouse ACC TTC AAC ACC CCA GCC ATG  
3'  $\beta$ - actin mouse GCT CGG TCA GGA TCT TCA TGA GG

5' VH- MOG- outside GCT ACA CAT TCA GTA GCT TC  
3' VH- MOG- outside GTA TGG CAT GTT TAC CAT CG  
5' VH- MOG- inside TCA GTA GCT TCT GGA TAG AG  
3' VH- MOG- inside GTA TGG CAT GTT TAC CAT CGT ATT AC

5' VH- A20- outside GTT ACA ATT TCT CCG ACA AG  
3' VH- A20- outside GTC GCA GGC GGA ATA ATC AC  
5' VH- A20- inside TCT CCG ACA AGT GGA TTC AC

3' VH- A20- inside GCA GGC GGA ATA ATC ACC CG

Gene sequences of A20 were kindly provided by Dr. Ralph Mocikat, GSF München and Michael Hallek), MOG gene sequences provided by Marcel Zocher.

PCR was performed (30 cycles 0.5min DNA synthesis each cycle and 55°C annealing temperature; Robocycler<sup>R</sup>, Stratagen, La Jolla, USA). Each PCR reaction contained 1 µl cDNA, 1 µl forward primer (from stock 10 µM), 1 µl reverse primer (from stock 10 µM), 2 µl dNTPs (from stock 2 mM each), 2 µl 10x TAQ Puffer (Sigma-Aldrich Chemie GmbH Munich, Germany), 0.2 µl TAQ- Polymerase (conc. 5 U/µl, Sigma-Aldrich Chemie GmbH Munich, Germany), 12.8 µl H<sub>2</sub>O. The DNA amplification results were analysed on a standard analytical agarose gel. The result of this nested PCR was that the MOG primers amplified specifically just DNA from MOG cells, not from A20 cells and the A20 primers amplified specifically just DNA from A20 cells, not from MOG cells (Figure 3A). As a positive control β- actin was amplified to test the quality of the cDNA and the PCR reactions.

#### *B) RNA isolation and reverse transcription from single B cells*

Sorted mouse B cells from example 1 were tested using MOG- and A20-specific nested PCR. A number of 8 sorted B cells was used for this test. Each of these 8 B cells was contained in 160µl FACS buffer. The cells were lysed by adding 480µl lysis-/binding buffer (DynaL Biotech GmbH, Hamburg, Germany, Dynabeads mRNA direct micro kit). At this point cells were stored at -20°C. As positive controls a pool of 200 A20 cells and another pool of 200 MOG cells were lysed in parallel with the sorted single cells.

In the next step the RNA of the lysed cells was coupled to magnetic beads (DynaL Biotech GmbH, Hamburg, Germany, Dynabeads mRNA direct micro kit). Before coupling beads were washed: 10 x 20µl Dynabeads were washed in 200µl lysis buffer. Beads were magnetically separated and the supernatant was discarded. This washing procedure was repeated two more times. Finally, beads were resuspended in 11 µl lysis buffer each. Subsequently 10µl washed Dynabeads were added to each of the 10 RNA samples. The RNA and the beads were incubated under mixing for 10min at room temperature. Subsequently, magnetic separation was performed, the supernatant was removed and the beads were

washed two times with 100 $\mu$ l washing buffer A (DynaI Biotech GmbH, Hamburg, Germany, Dynabeads mRNA direct micro kit) and one time with 100 $\mu$ l WBI-buffer (50 mM Tris/ HCL pH 8.0, 75 mM KCL, 10 mM DTT, 0.25% IGEPAL). After the last washing step the beads were resuspended with 7 $\mu$ l H<sub>2</sub>O for elution of RNA from the beads.

The isolated RNA was subsequently subjected to a cDNA synthesis step. In contrast to the test experiment (see A above) a mixture of the outer primers was used for the cDNA synthesis from single cells: 1) 0.5  $\mu$ l/sample 3'- VH A20-outside (10  $\mu$ M stock); 2) 0.5  $\mu$ l/ sample 3'- VH MOG-outside (10  $\mu$ M stock). An amount of 1 $\mu$ l primer mixture was added to each RNA probe. To allow primer annealing, samples were denatured for 3min at 65°C. Samples were placed on ice for 5min immediately after the annealing step. Reverse transcription was carried out using Sensiscript RT Kit, Qiagen, Hilden, Germany (2  $\mu$ l 10 x Sensiscript RT-buffer, 2  $\mu$ l dNTPs 5 mM each, 1  $\mu$ l Sensiscript-Reverse Transcriptase, 7  $\mu$ l H<sub>2</sub>O). Reverse transcription was performed at 37°C for 60min followed by a denaturation step at 95°C for 5min. Samples were stored on ice.

### *C) Nested PCR with single sorted mouse B cells*

For DNA amplification the following nested PCR was carried out for each sample: First round of DNA amplification was performed using the outer primer pairs (cycler and program see above A but with 40 cycles instead of 30 cycles). Two reactions were performed for each sample. Reaction 1 contained the 5'VH MOG outside and the 3'VH MOG outside primer pair and a reaction 2 contained the 5'VH A20 outside and the 3'VH A20 outside primer pair.

A second round of PCR amplification was performed using the inner primer pairs (cycler and program see above A with 40 cycles instead of 30 cycles) and 3 $\mu$ l of the first round PCR as DNA template. Again, for each sample two reactions were performed. Reaction 1 contained the 5'VH MOG inside and the 3'VH MOG inside primer pair and a second reaction contained the 5'VH A20 inside and the 3'VH A20 inside primer pair. The DNA amplification results were analysed on a standard analytical agarose gel. The result of this nested PCR amplification is seen in Figure 3B and 3C. All eight cells were MOG positive as well as the MOG cell control containing the MOG 200 cells pool. As expected, the A20 200 cells pool didn't show

any signal in the MOG nested PCR neither did the water control. The results of the A20 nested PCR showed no specific PCR amplified signal in 7 out of the 8 single sorted cells tested. The sample containing cell number 3 showed MOG as well as A20 PCR amplified signal. It is likely that sample number three actually contained 2 cells, one MOG cell and a contaminating A20 cell. This might well be the result of manual sample collection.

### Example 3

#### Specificity of FRET selection, dilution series experiments

This experiment employs a dilution series of IgG positive, MOG-Fc specific 8.18C5 mouse B cells in IgG positive but antigen unspecific A20 mouse B cells to determine the specificity of the FRET selection method. First the FRET gate was set using a double stained 8.18C5 B cell population. Thereafter, dilutions of double stained 8.18C5 B cells in A20 cells were measured. The ratio of double stained 8.18C5 B cells used and cells measured in the FRET gate reflects the specificity of the FRET method. Additional, A20 cells were used to control the FRET gate. Labelling reactions were performed in a 96 well plate format. A number of 200 000 cells was added to each well. Reactions 1-7 were used as controls to determine the FACS gate settings. Labelling reaction 2 for unstained A20 cells contained 48.5µl A20 cells (fresh from cell culture,  $4.12 \times 10^6/\text{ml}$ ) and 200µl FACS buffer (1% BSA, 0.05% sodium azid), set up four times. Labelling reaction 2 for unstained 8.18C5 cells contained 83µl 8.18C5 cells (fresh from cell culture,  $2.4 \times 10^6/\text{ml}$ ) and 50µl FACS buffer. Labelling reaction 3 for IgG stained A20 cells as control of overshining (first compensation FI2 – FI1) contained 48.5µl A20 cells and 200µl FACS buffer and 10µl goat anti mouse IgG-fluorescein 0.48 mg/ml (Micromet Lot 12.07.01, Munich). Labelling reaction 4 for double stained A20 cells as control for unspecific MOG-binding contained 48.5µl A20 cells and 250µl FACS buffer and 25µl goat anti mouse IgG-fluorescein and 25µl MOG-Fc Alexa Fluor 564, 0.527 mg/ml (Micromet Lot PH2024, Munich). Labelling reaction 5 for MOG-Fc single stained 8.18C5 cells as control for FL2 by residual excitement of Alexa Fluor 546 contained 83µl 8.18C5 cells and 50 µl FACS-Puffer and 5µl MOG-Fc Alexa Fluor 546. Labelling reaction 6 for IgG single stained 8.18C5 cells with setting of the amplification (FL2 – FL1 / FL3

– FL2) contained 83 $\mu$ l 8.18C5 cells and 100  $\mu$ l FACS-Puffer and 10 $\mu$ l goat anti mouse IgG-fluorescein. Labelling reaction 7 for double stained 8.18C5 cells with settings for the FRET region contained 83 $\mu$ l 8.18C5 cells and 200 $\mu$ l FACS-Puffer and 20 $\mu$ l goat anti mouse IgG-fluorescein and 20 $\mu$ l MOG-Fc Alexa Fluor 546.

Reactions 8-18 were set up as dilution series (see table). All reactions contained 48.5 $\mu$ l (=200 000) A20 cells (fresh from cell culture,  $4.12 \times 10^6$ /ml), 20 $\mu$ l goat anti mouse IgG-fluorescein and 20 $\mu$ l MOG-Fc Alexa Fluor 546. Additionally, the reactions contained decreasing numbers of 8.18C5 cells (from 200 000 cells in 1:2 dilution steps down to 195 cells). Therefore, 83 $\mu$ l, 41.5 $\mu$ l, 20.75 $\mu$ l, 10.4 $\mu$ l, 5.2 $\mu$ l, and 2.6 $\mu$ l of 8.18C5 cells (fresh from cell culture,  $2.4 \times 10^6$ /ml) were added to reactions 8-13 respectively. Further, 13 $\mu$ l, 6.5 $\mu$ l, 3.24 $\mu$ l of 1:10 diluted 8.18C5 cells were added to reactions 14 to 16, respectively. Finally, 16.2 $\mu$ l and 8.1 $\mu$ l of 1:100 diluted 8.18C5 cells were added to reactions 17-18, respectively.

The FACS control reactions 5, 6 and 7 are shown in Fig 4A, B and C. The separation of the double stained A20 and the 8.18C5 B cells is shown in Fig 4 D. The graph of all dilution reactions is shown in Fig 5. The table below summarises the results of the dilution experiment. The values of the strongest dilutions (reactions 14-18) deviate somewhat from the expected values due to low IgG signal on the 8.18C5 cells.

reaction	cells in R1	A20	8.18C5	% expected 8.18C5	cells expected 8.18C5	sorted 8.18C5 (R2)
8	5245	200.000	200.000	50,0	2623	2858
9	5188	200.000	100.000	33,3	1729	1755
10	5183	200.000	50.000	20,0	1037	1111
11	5180	200.000	25.000	11,1	576	760
12	5183	200.000	12.500	5,9	305	512
13	5183	200.000	6.250	3,0	157	128
14	5183	200.000	3.125	1,5	80	47
15	5180	200.000	1.563	0,8	40	43
16	5198	200.000	781	0,4	20	44
17	5161	200.000	391	0,2	10	29
18	5203	200.000	195	0,1	5	22

The dilution experiment as performed here demonstrates the high specificity of the FRET selection method.

#### **Example 4**

##### **Selection of single B cells from human blood using FRET**

###### ***A) Isolation of PBMCs***

To isolate human peripheral blood mononuclear cells (PBMCs) 500 ml heparinized blood were collected from a healthy donor. The blood was diluted 1:1 with PBS (Phosphate Bufferd Saline). The resuspended blood cells were separated using a Ficoll density gradient (Ficoll-Paque from Amersham, density 1.077 g/ml). A centrifuge tube was filled with 15 ml Ficoll solution and gently overlaid with 30 ml of the blood/PBS mixture. The gradient was centrifuged at 600g<sub>av</sub> for 30min at 20°C. PBMCs were removed from the gradient and transferred to a fresh tube. A volume of 45ml FACS-buffer (1% FCS in PBS) was added to the PBMCs to wash the cells. Cells were spun down at 600g<sub>av</sub> for 10 min, the supernatant discarded and cells resuspended in further 15 ml of FACS-buffer (1% FCS in PBS, no azid). PBMCs were counted using a Neubauer chamber.

B cells were isolated from PBMCs using Miltenyi purification. The B Cell Isolation Kit is an indirect magnetic labeling system which is used to obtain untouched B cells from peripheral blood by the magnetic depletion of T cells, NK cells, monocytes, granulocytes, platelets and erythroid precursor cells. A cocktail of hapten-modified CD2, anti-IgE, CD4, CD11b, CD16 and CD36 antibodies is used for labeling non-B cells. In a second step, non-B cells are magnetically labeled using MACS MicroBeads coupled to an anti-hapten antibody (Bauer et al.,1999, Immunol. 97, 699-705). The protocol was performed as described (Milteny B cell isolation kit, Milteny, Auburn,CA). Cells were counted and resuspended in 10%FCS/PBS no azid (MACS buffer) at a concentration of  $4.25 \times 10^6$  cells/ml.

###### ***B) Labeling of the detection molecules rCD28 antigen and anti human IgD antibody***

Before the actual labeling of cells the fluorophores fluorescein and Alexa Fluor 546 were attached to polyclonal rabbit anti human IgD antibody 1 mg/ml in TRIS-buffer

(DAKO A0093, Hamburg, Germany) and recombinant CD28-mulg 0.5 mg/ml in phosphat/potassium-buffer (Ancell Corp., Bayport, USA) respectively. Human CD28 is an important costimulatory molecule found on all CD4+ T cells and on about half of the CD8+ T cells. T cell activities attributed to CD28 include prevention of anergy, induction of cytokine gene transcription, stabilization of cytokine mRNAs and activation of CD8+ cytotoxic T lymphocytes. Ancell's rCD28 is a soluble fusion protein consisting of the extracellular (134 aa) domain of human CD28 fused to murine IgG2a Fc (232 aa).

Anti human IgD antibody and rCD28 antigen were dialyzed against borate buffer pH 8.5 (0.1 M NaCl, 0.05 M Borate, H<sub>2</sub>O Ampuwa) for 3 x 1h in dialysis tubing (Roth Visking, MWCO 10.000). The protein amount after dialysis was measured (Bradford Reagent, Biorad) using a bovine IgG protein standard 2 mg/ml in PBS (Pierce 23212, Pierce Biotechnology, Rockford, IL, USA) and anti human IgD antibody and rCD28 antigen concentrations were calculated. The concentrations of anti human IgD antibody and rCD28 after dialysis was 1.445 mg/ml and 1.064 mg/ml, respectively.

The fluorochromes fluorescein-NHS, 1.1 mg/ml in DMSO (Fluka 46940, Riedel-de Haen, Sigma-Aldrich, Seelze, Germany) and Alexa Fluor 546 NHS, 5 mg/ml in DMSO (Molecular Probes, Eugene, OR, USA) were subsequently conjugated to anti human IgD antibody and rCD28 respectively. For each molecule two conjugation reactions were carried out: one having a 10fold molar excess of the fluorochrome and the other one having a 5fold molar excess of the fluorochrome.

In a first reaction 100 $\mu$ l anti human IgD antibody and 5 $\mu$ l fluorescein-NHS, 1.1 mg/ml in DMSO (Fluka, Riedel-de Haen, Sigma-Aldrich, Seelze, Germany) were incubated for 1h on the Vortex (IKA Technologies, Germany).

In a second reaction 100 $\mu$ l anti human IgD antibody and 2.5 $\mu$ l fluorescein-NHS, 1.1 mg/ml in DMSO (Sigma-Aldrich Chemie GmbH Munich, Germany) and 2.5 $\mu$ l DMSO (HPLC grade, Fluka, Riedel-de Haen, Sigma-Aldrich, Seelze, Germany) were incubated for 1h on the Vortex (IKA Technologies, Germany).

In a third reaction 100 $\mu$ l rCD28 and 1.44 $\mu$ l Alexa Fluor 546 NHS, 5 mg/ml in DMSO (Molecular Probes, Eugene, OR, USA) and 3.56 $\mu$ l DMSO were incubated for 1h on the Vortex (IKA Technologies, Germany).



In a fourth reaction 100 $\mu$ l rCD28 and 0.72 $\mu$ l Alexa Fluor 546 NHS, 5 mg/ml in DMSO (Molecular Probes, Eugene, OR, USA) and 4.28 $\mu$ l DMSO were incubated for 1h on the Vortex (IKA Technologies, Germany).

The conjugates were purified using 2ml P60 gel each equilibrated with PBS, 0.05% sodium azide. Reaction 1 was used for B cell selection.

### *C) Labeling of the B cells*

The isolated cells from A) were divided up into four small labeling reactions used as controls and into one big labeling reaction used for the sort.

The first labeling reaction contained unstained cells. Therefore, 400 000 cells were diluted into 100 $\mu$ l FACS buffer (= 1% heat-inactivated FCS in PBS without calcium and magnesium, pH 7.4).

The second labeling reaction contained single stained cells with the green fluorescence donor fluorescein. Therefore, 400 000 cells were diluted into 100 $\mu$ l FACS buffer and 10 $\mu$ l of rabbit anti human IgD-fluorescein (Micromet Lot. PH2006, Munich) were added.

The third labeling reaction contained a control for self fluorescence of the acceptor fluorochrome Alexa Fluor 546 (25% anti human IgD-Alexa Fluor 546 and 75% non fluorescently marked rabbit anti human IgD antibody). Therefore, 2.5 $\mu$ l of non fluorescently marked rabbit anti human IgD antibody A0093, 1 mg/ml in borate buffer pH 8.5, ca. 1mg/ml (DAKO, Hamburg, Germany) and 2.5 $\mu$ l of rabbit anti human IgD-Alexa Fluor 546, ca. 0.3 mg/ml (Micromet Lot. PH2006, Munich) were mixed together in a reaction tube and then added to 400 000 cells diluted in 100 $\mu$ l FACS buffer.

The fourth labeling reaction contained an IgD double staining as positive control and guidance for the gate setting. Therefore, 15 $\mu$ l of rabbit anti human IgD-fluorescein (Micromet Lot. PH2006, Munich) and 5 $\mu$ l of rabbit anti human IgD-Alexa Fluor 546, ca. 0.3 mg/ml (Micromet Lot. PH2006, Munich) were mixed together in a reaction tube and then added to 400 000 cells diluted in 100 $\mu$ l FACS buffer (1% heat-inactivated FCS in PBS without calcium or magnesium, pH 7.4).

A large labelling reaction used for actual sorting contained all remaining cells diluted in 15ml FACS buffer. Therefore, 100 $\mu$ l of rabbit anti human IgD-fluorescein 0.3 mg/ml (Micromet Lot. PH2006, Munich) and 100 $\mu$ l of rCD28-Alexa Fluor 546 0.21

mg/ml in PBS containing 0.05% sodium azid, (Micromet Lot PH2006, Munich) were mixed together and added to the cells.

The labeling reactions was incubated for 30min at 4°C, then washed twice with FACS buffer. Each of the four control reactions was resuspended in 400µl FACS buffer containing 0.5µg/ml Propidiumiodide as a death marker. The sorting reaction was resuspended in 400µl FACS buffer containing 0.5µg/ml Propidiumiodide as a death marker.

#### *D) FACS sort preparations*

Before FACS sorting was started the FACS-flow containers were rinsed with PBS pH 7.4 diluted from stock with Ampuwa H<sub>2</sub>O. Subsequently, the FACS-flow container was filled with PBS containing no azid and the probe collection tube filled with Ampuwa H<sub>2</sub>O was placed at the collection position. The control panels of the FACS liquid system were set to run and the acquisition control was set to aquire. The whole system was washed for 5 min. After that the machinery was kept at standby.

#### *E) FACS settings*

The labelling reactions from C) were used to adjust FACS settings, select compensation and finally choose appropriate settings. This was achieved by performing several measurement steps.

For the first labelling reaction (unstained cells) the compensation was set to 0, FL1 – FL3 to  $10^0 - 10^1$ .

For the second labelling reaction (single stain with anti IgD-fluorescein) the compensation was set to FL2-FL1 ca. 25%, compensation for FL3-FL2 ca. 4%.

For the third labelling reaction (25% anti IgD-Alexa546 and 75% non-fluorescent anti-IgD) the gridlock setting was set to highest FL2.

For the fourth labelling reaction (anti IgD-fluorescein and anti IgD-Alexa546) the Gate settings for fluorescence resonance energy transfer (FRET) were set above Alexa Fluor 546 auto-fluorescence.

For the large labelling reaction for FACS sort (anti IgD-fluorescein and rCD28-Alexa Fluor 546) the gate settings were the same as from labelling reaction four.

The gate for selection of living cells represented a combination of three criteria. On one hand the gate restricted the selected cells to the FSC/SSC living population (low granularity) on the other hand only FL1 positive cells (=IgD+) were selected and as third criterium only FL3 negative cells (no propidiumiodide staining) were selected.

#### *F) FACS sort procedure*

Just before the actual sorting process, the FACS sort machine was washed again with PBS at high flow rate. Immediately after this, the actual flow sort was initiated by switching to a low flow rate of 12  $\mu$ l/sec. This flow rate equals an analysis of 1500 cells/sec. Cells were diluted 1:2 in MACs-buffer just before sorting. For sorting results see Fig. 6A-D. Figure 6A showed FACS signals of unstained cell. Figure 6B showed the background caused by fluorescein donor dye on its own as a control. Figure 6C showed the background of Alexa Fluor 546 acceptor dye staining. The double stained cells from labeling reaction four (see example 4C) were used as guidance to set the gate for selection (Fig. 6D).

Auto-reactive B cells having bound rCD28-Alexa Fluor 546 antigen and anti IgD-fluorescein simultaneously could be identified using FACS sort due to the high stringency of fluorescence resonance energy transfer (FRET) signals. The sort results show that a minute number of cells was selected as FRET-positive (Fig. 6E). For further validation of these selected B cells single clones were analyzed using VH and VL PCR cloning.

### **Example 5**

#### **Cloning of VH and VL regions from isolated B-cells**

##### *A) RNA isolation and cDNA synthesis*

The VH and VL antibody chains were cloned from several isolated cells. The single B cells were collected in a volume of 160  $\mu$ l FACS buffer, lysed with 480  $\mu$ l lysis/binding buffer (Dynal Biotechnology GmbH, Hamburg, Germany) and stored at -20°C. The washing of the Dynabeads and the RNA extraction procedure was performed as described above (example 2B). For cDNA synthesis a primer mix was

generated containing four different 3'-primers. Each primer binds to the constant region:

M For 1: TGG CAG ATG AGC TTG GAC TTG

K For: ACA CTC TCC CCT GTT GAA GCT

L For: GTG CTC CCT TCA TGC GTG AC

Hu,  $\beta$ - actin For 3: ACT CGT CAT ACT CCT GCT TGC

Reactions contained 0.5  $\mu$ l/ Probe heavy chain primer M For 1 (10  $\mu$ M stock), 0.5  $\mu$ l/ Probe light chain kappa primer K For (10  $\mu$ M stock), 0.5  $\mu$ l/ Probe light chain lambda primer L For (10  $\mu$ M stock), 0.5  $\mu$ l/ Probe  $\beta$ - Actin primer hu.  $\beta$ - actin For 3 (10  $\mu$ M stock). Annealing of 2 $\mu$ l primer mix to each sample was performed at 65°C for 3min. Samples were placed on ice for 5 min immediately after the annealing step. Reverse transcription was carried out using Sensiscript RT Kit, Qiagen, Hilden, Germany, Cat. Nr. 205 213 (2  $\mu$ l 10 x Sensiscript RT-buffer, 2  $\mu$ l dNTPs 5 mM each, 1  $\mu$ l Sensiscript-Reverse Transcriptase, 6  $\mu$ l H<sub>2</sub>O). Reverse transcription was performed at 37°C for 60min followed by a denaturation step at 95°C for 5min. Samples were stored on ice.

#### *B) Half nested PCR amplification of VH and VL regions*

In the half nested PCR two rounds of DNA amplification are performed as with nested PCR. However, during half nested PCR the 5' primers stayed constant for both PCR amplification steps and only the 3' primers were shifted inside during the second round of PCR.

For the first round PCR the following primers were used:

M 1	heavy chain	Primer: hu CH 1 M For	+	hu VH back MIX
K1	light chain kappa	Primer: K For 2	+	hu VK back MIX
L 1	light chain lambda	Primer: L For 2	+	hu VI back MIX
B 1	$\beta$ - Actin chain	Primer: hu $\beta$ - actin For 2	+	hu $\beta$ - actin back1

HUCH1MFOR: TGG AAG AGG CAC GTT CTT TTC TTT

KFOR2: AGT TAC CCG ATT GGA GGG CG

LFOR2: CCT TCC AGG CCA CTG TCA C

HUBACTINBACK1: GTG GGG CGC CCC AGG CAC CA

HUBACTINFOR2: GAT GGA GGC GGC GAT CCA CAC GG

hu VH back MIX:

HUVHBACK1: CAG RTG CAG CTG GTG CAR TCT GG  
 HUVHBACK2: SAG GTC CAG CTG GTR CAG TCT GG  
 HUVHBACK3: CAG GTC CAG CTT GTA CAG TCT GG  
 HUVHBACK4: SAG RTC ACC TTG AAG GAG TCT GG  
 HUVHBACK5: SAG GTG CAG CTG GTG GAR TCT GG  
 HUVHBACK6: GAG GTG CAG CTG KTG GAG WCY GG  
 HUVHBACK7: CAG CTG CAG CTA CAG CAG TGG GG  
 HUVHBACK8: CAG STG CAG CTG CAG GAG TCS GG  
 HUVHBACK9: GAR GTG CAG CTG GTG CAG TCT GG  
 HUVHBACK10: CAG GTA CAG CTG CAG CAG TCA GG

hu VK back MIX:

HUV<sub>k</sub>BACK1: GAC ATC CRG DTG ACC CAG TCT CC  
 HUV<sub>k</sub>BACK2: GAA ATT GTR WTG ACR CAG TCT CC  
 HUV<sub>k</sub>BACK3: GAT ATT GTG MTG ACB CAG WCT CC  
 HUV<sub>k</sub>BACK4: GAA ACG ACA CTC ACG CAG TCT CC  
 HUV<sub>k</sub>BACK5: GAT GTT GTG ATG ACT CAG TCT CC  
 HUV<sub>k</sub>BACK6: GAT ATT GTG ATG ACC CAC ACT CC  
 HUV<sub>k</sub>BACK7: GAA ATT GTG CTG ACT CAG TCT CC

hu VL back MIX:

HUV<sub>λ</sub> BACK1: CAG TCT GTS BTG ACG CAG CCG CC  
 HUV<sub>λ</sub> BACK2: TCC TAT GWG CTG ACW CAG CCA C  
 HUV<sub>λ</sub> BACK3: TCC TAT GAG CTG AYR CAG CYA CC  
 HUV<sub>λ</sub> BACK4: CAG CCT GTG CTG ACT CAR YC  
 HUV<sub>λ</sub> BACK5: CAG DCT GTG GTG ACY CAG GAG CC  
 HUV<sub>λ</sub> BACK6: CAG CCW GKG CTG ACT CAG GCM CC  
 HUV<sub>λ</sub> BACK7: TCC TCT GAG CTG AST CAG GAS CC  
 HUV<sub>λ</sub> BACK8: CAG TCT GYY CTG AYT CAG CCT  
 HUV<sub>λ</sub> BACK9: AAT TTT ATG CTG ACT CAG CCC C

HUV $\lambda$  BACK10: CAG TCT GTG CTG ACT CAG CCA CC  
 HUV $\lambda$  BACK11: CAA TCT GCC CTG ACT CAG CCT  
 HUV $\lambda$  BACK12: TCT TCT GAG CTG ACT CAG GAC CC  
 HUV $\lambda$  BACK13: CAC GTT ATA CTG ACT CAA CCG CC  
 HUV $\lambda$  BACK14: CAG GCT GTG CTG ACT CAG CCG TC  
 HUV $\lambda$  BACK15: CWG CCT GTG CTG ACT CAG CCM CC

Sequence symbols are: A (adenin), C (cytosine), G (guanosin), T (thymidin), I (inosin), U (uracil). Wobble IUPAC-IUB symbols are: R (A or G), Y (C or T), M (A or C), K (G or T), S (G or C), W (A or T), H (A or C or T), B (G or T or C), V (G or C or A), D (G or T or A), N (G or A or T or C).

Primers were slightly modified according to de Haard et al, 1999, JBC 274, 18218-18230; Sblattero and Bradbury, 1998, Immunotechnology 3, 271- 278.

Subsequent PCR was performed (HotStar TAQ, QIAGEN, Hilden, Germany, Cat.Nr. 203443) on a RoboCycler<sup>R</sup> (Stratagen, La Jolla, USA) using 40 cycles of DNA synthesis 0.5min each cycle at 55°C annealing temperature).

A second round of PCR amplification was performed using the following primers and 3 $\mu$ l of the first round PCR as DNA template (cycler and program as above):

M2	heavy chain	Primer: IgM For	+	hu VH back MIX
K2	light chain lambda	Primer: IgK For	+	hu VK back MIX
L2	light chain kappa	Primer: IgL For	+	hu VL back MIX
B2	$\beta$ - actin chain	Primer: hu $\beta$ -actin For1	+	hu $\beta$ - actin back1

IGMFOR: GGT TGG GGC GGA TGC ACT CC  
 IGKFOR: GAT GGT GCA GCC ACA GTT CG  
 IGLFOR: GGA GGG YGG GAA CAG AGT GAC  
 HUBACTINFOR1: CTC CTT AAT GTC ACG CAC GAT TTC

The DNA amplification results were analysed on a standard analytical agarose gel. The half nested PCR results in several of the cells tested showed amplification of both V chains on the first try. A few cells immediately tested positive for VH and VL.

### *C) Subcloning of VH and VL regions*

The bands of VH and VL amplification fragments from example 5B were excised and isolated from the agarose gel. The isolated DNA fragments were subcloned into pCR2.1-TOPO (Invitrogen GmbH, Karlsruhe, Germany), clones were picked, plasmid DNA isolated and sequenced.

For each single cell one VH and one VL sequence was selected, which displayed the complete sequence including leader sequence and all functional sequence, the CDRs 1-3 and corresponding framework, which had no stop-codon mutation, nor frame shift and were clearly germ line sequences.

### *D) Fusion PCR for generation of scFvs from different VH and VL regions*

The cloned VH and VL sequences were fused together employing a fusion PCR technique. For selected clones linker primers were designed containing specific V sequence from the clone and additional linker sequence. VL and VH were fused together in the order of VL-VH, whereby the first linker primer was a 3' linker for the VL clone plus linker sequence and the second linker primer was a 5' linker for the VH clone plus linker sequence. The following principle sequence was used for the fusion primers:

VL 3' linker primer: GGA GCC GCC GCC GCC AGA ACC ACC ACC ACC (X)<sub>n</sub>

VH 5' linker primer: TCT GGC GGC GGC GGC TCC GGT GGT GGT GGT TCT (X)<sub>n</sub>

(X)<sub>n</sub> denotes a variable number of nucleotides which are part of the sequence of specific VL or VH clones. The length of VL or VH specific sequence incorporated within these fusion primers depends upon the GC content of the sequence. This primer design allows to achieve an approximate overall oligonucleotide melting temperature of 68°C, which is favourable for PCR amplification.

A first PCR amplification was performed using a VL sequence specific 5' forward primer and the VL 3' linker primer (RoboCycler<sup>R</sup> Stratagene, La Jolla, USA, 30 cycles 1 min DNA synthesis and 55°C annealing temperature).

A second PCR amplification was performed under the same conditions using the VH 5' linker primer and a VH sequence specific 3' primer.

The amplified PCR products were purified on an agarose gel and, subsequently, the VL and VH specific bands were cut out and isolated from the gel (Qiaex kit, Qiagen, Hilden, Germany). Each DNA was resuspended in 50  $\mu$ l H<sub>2</sub>O. Thereof, 3  $\mu$ l were used for further fusion PCR amplification. In the fusion PCR amplification the previously amplified and isolated VL and VH chains were mixed together and amplified using the outer VL and VH specific primers already used in the first amplifications (3  $\mu$ l of each V chain template DNA, 3  $\mu$ l of each primer, 6  $\mu$ l dNTPs (10  $\mu$ M stock), 6  $\mu$ l 10xbuffer from Sigma-Aldrich, 0.6  $\mu$ l Taq polymerase from Qiagen, 35.4  $\mu$ l H<sub>2</sub>O, RoboCycler<sup>R</sup> Stratagene, 10 cycles with 1.5 min DNA synthesis at 55°C annealing temperature). Due to the overlap in the linker sequences one continuous VL-linker-VH fusion product was amplified. This PCR fusion product was purified on an agarose and isolated as described above. The resuspended isolation products were cut enzymatically to create the appropriate 5' and 3' overhangs for subcloning into a vector for example Bluescript (Sambrook & Russel: Molecular Cloning: A Laboratory Manual, third edition 2001, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York). The created plasmid was transformed into competent cells for example XL-1-blue cells (Stratagene, La Jolla, USA). Several of those transformed clones were picked, cultivated, plasmid DNA isolated from those cultivated cells and their identity verified by means of analytical enzymatical digest and sequencing or the like.

#### *E) Expression of cloned scFvs and binding assays*

Sequence verified scFv clones were used for further subcloning into an expression vector system like pEF DHFR (Invitrogen, USA). The scFv clones created had the structure: Leader- VL- (G<sub>4</sub>S)<sub>3</sub>- VH- Flag. Other structure orientations may be achieved by using a different fusion strategy. Transfected CHO cells transiently expressed the scFv constructs using standard protocols (Sambrook & Russel: Molecular Cloning: A Laboratory Manual, third edition 2001, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York). For further preservation of the clones, stable expressing CHO transfectants were selected for each scFv also according to the state of the art.

To confirm the specificity of the scFv clone the culture supernatant of scFv expressing CHO cells was used in an ELISA binding assay.



The isolated and verified VH and VL sequences could further be used to generate a variety of antibody constructs comprising single chain antibodies, bispecific antibody constructs and complete immunoglobulin formats.

### **Reference Example 1**

#### **Multi color sort of human B cells for EpCAM binders**

##### ***A) Isolation of CD19<sup>+</sup> cells***

Peripheral human blood mononuclear cells (PBMCs) were isolated using a Ficoll density gradient (Ficoll-Paque from Amersham, density 1,077 g/ml) according to manufacturer's protocol. Subsequently,  $200 \times 10^6$  cells were incubated with 100  $\mu$ l CD19 beads for 15 min at 4°C to isolate CD19<sup>+</sup> cells. After washing and filtering  $6.9 \times 10^6$  cells were counted.

##### ***B) Labeling and FACS detection of cells***

The isolated cells were divided up into seven reaction tubes ( $\sim 1 \times 10^6$  cells per 1ml) and incubated with different amounts of Cy2-labeled EpCAM antigen (5.00  $\mu$ g/ml, 2.50  $\mu$ g/ml, 1.25  $\mu$ g/ml, 0.63  $\mu$ g/ml, 0.31  $\mu$ g/ml). Another reaction contained unstained cells. A control reaction tube contained Cy2 labeled anti-CD45. All tubes were incubated at 4°C for 30min. Cells then were incubated with a goat anti human IgD polyclonal antiserum, which had been labeled with phycoerythrin (PE). Subsequently performed FACS sorting results are shown in Figure 7A-F. In comparison to the anti-CD45 control (Fig. 7F), which showed a fluorescent shift (FL1-H) of nearly all B cells, the EpCAM stained cells showed hardly any shifted cells (Fig 7A-E). Nevertheless, single cells with high fluorescent signals on both channels (FL2-H and FL1-H) were sorted by FACS.

##### ***C) Binding assay with EpCAM isolated scFvs***

The RNA from single FACS sorted cells was isolated and the VH and VL regions were cloned via RT-PCR as described in example 2B and 5. After subcloning, supernatant from three subclones scEpCAM20-5, scEpCAM20-6 and scEpCAM20-7

were tested in FACS-based binding assays using KATOIII cells and CHO 17-1A cells (Fig. 8) as EpCAM positive cell lines. In both assays, bispecific scFv anti-EpCAM x anti-CD3, a known single chain antibody having anti-EpCAM specificity was used as positive control (Fig. 8 green line). Anti-His tag antibody and anti-EGFR antibody were used as negative control (Fig. 8 black line and pink line respectively). While bispecific scFv anti-EpCAM x anti-CD3 showed good binding in both assays, none of the other substances showed any EpCAM binding specificity. The multi color sort of human B cells for EpCAM binders using Cy2 (similar to fluorescein) and phycoerythrin (PE) fluorescent labels resulted in no specific binders.

Several reasons attributed to this result. Fluorescein works as a donor dye for phycoerythrin (PE). PE is a big protein molecule that has a molecular weight of 240 kD and its spectrum largely overlaps with fluorescein (Fig. 9). So in the described method, an IgD bound antigen would be surrounded by several polyclonal anti IgD-PE conjugates. This would cause a partial decrease of fluorescein signal due to PE size and spectrum overlap, since both fluorochromes are very close together.

Furthermore, the PE conjugates like the one of the rabbit anti-fluorescein/Oregon Green IgG antibody (A-21250, Anti-Fluorescein/Oregon Green Antibodies and Conjugates) have the unique characteristics of both shifting the green-fluorescence emission of fluorescein-labeled probes to longer wavelengths and greatly intensifying the long-wavelength signal ([www.probes.com/handbook/sections/0704.html](http://www.probes.com/handbook/sections/0704.html)).

Additionally, it has been reported (Szaba et al., 1992, Biophys. J. 61(3), 661-70) that the energy transfer efficiency was down to approximately 20% between the CD4 epitopes OKT4-FITC and Leu-3a-PE as well as between OKT4E-FITC and OKT4-PE due to photobleaching. Between OKT4E-FITC and Leu4-PE energy transfer efficiency was down even further to 8% and barely detectable between OKT4-FITC to Leu-5b-PE.

## Claims

1. A method of identifying a B cell carrying a surface immunoglobulin molecule having a binding site for an antigen of interest comprising
  - (a) contacting a sample putatively containing said B cell
    - (aa) with the antigen of interest wherein said antigen is labeled with a first label; and
    - (ab) with a receptor specifically binding to said surface immunoglobulin molecule wherein said receptor is labeled with a second label; andwherein said first label, when being brought into a spatial proximity of between 10 and 100 Angstrom with said second label emits a detectable signal upon activation of said second label by an external source; and
  - (b) assessing the presence of said detectable signal, wherein said presence is, in turn, indicative of the B cell carrying a surface molecule having a binding site for the antigen of interest.
2. The method of claim 1, wherein said B cell is an autoreactive B cell.
3. The method of claim 1 or 2 wherein said surface immunoglobulin molecule is an IgD, an IgE, an IgM or an IgG.
4. The method of any one of claims 1 to 3, wherein said B-cell is a naïve, IgD-positive B-cell.
5. The method of any one of claims 1 to 4, wherein said antigen of interest is selected from the group consisting of
  - (a) auto-antigens
  - (b) allergens; and
  - (c) immunoglobulins

6. The method of any one of claims 1 to 5, wherein said sample is a sample of essentially purified B cells.
7. The method of any one of claims 1 to 6, wherein said first label is a fluorophore or fluorochrome.
8. The method of any one of claims 1 to 7, wherein said second label is a fluorophore or fluorochrome.
9. The method of any one of claims 1 to 8, wherein said receptor is an antibody or a fragment or derivative thereof.
10. The method of claim 9, wherein said antibody is directed against the Fc-part of the surface immunoglobulin molecule.
11. The method of claim 10, wherein said antibody is an anti-idiotypic antibody, wherein said anti-idiotypic antibody does not interfere with the binding site to the antigen.
12. The method of any one of claims 1 to 11, further comprising the step of isolating identified B-cells.
13. The method of claim 12, further comprising the step of cloning VH- and VL-domains from identified B cells.
14. The method of claim 13, further comprising the step of expressing at least one of said V-domains in an expression system.
15. The method of claim 13 or 14, further comprising the step of generating antibodies or fragments or derivatives from said V-domains.

16. The method of claim 15, further comprising the steps of rearranging possible combinations of different VH and VL domains.
17. The method of claim 15 or 16, wherein said derivatives are bispecific antibody constructs or single chain antibodies.
18. The method of any one of claims 1 to 17, further comprising an assay for antibody evaluation.
19. The method of claim 18, wherein said evaluation assay is a binding assay.
20. The method of claim 19, wherein said binding assay is an ELISA or a FACS based binding assay.
21. A device for assessing the presence of a detectable signal as defined in claim 1, wherein said device comprises a closed system for the detection laser-beam and a catcher tube, and wherein the B cell of interest can be collected as a single cell by means of an electrochemical device which is triggered by an electric signal generated by the FAX device, wherein the electrochemical device moves the nozzle of the steady catcher tube liquid stream for a programmed time over a collecting tube, microtiter plate or other container after a B cell is sorted.


13. Nov. 2002

**Abstract**

The present invention relates to a method of identifying a B cell carrying a surface immunoglobulin molecule having a binding site for an antigen of interest comprising contacting a sample putatively containing said B cell with the antigen of interest wherein said antigen is labeled with a first label and with a receptor specifically binding to said surface immunoglobulin molecule wherein said receptor is labeled with a second label and wherein said first label, when being brought into a spatial proximity of between 10 and 100 Angstrom with said second label emits a detectable signal upon activation of said second label by an external source and assessing the presence of said detectable signal, wherein said presence is, in turn, indicative of the B cell carrying a surface molecule having a binding site for the antigen of interest.

1/25

Figure 1



2/25





Figure 2A



3/25




Figure 2B

4/25





Figure 2C

5/25




Figure 2D

6/25





Figure 2E

7/25




Figure 2F

8/25





Figure 2G

9/25




Figure 3A

10/25



Figure 3B



11/25




Figure 3C

12/25





Figure 4A





Figure 4B

14/25





Figure 4C

15/25





Figure 4D





Figure 4E

**Figure 5**




Figure 6 A-B








Figure 6 C-D

20/25



**Figure 6 E**



**Figure 7A-B**

22/25







Figure 7C-D




F



E

Figure 7E-F



**Figure 8**




Figure 9

PCT Application  
**PCT/EP2003/012664**





**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**